Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth reported Q1 2026 revenue of $27.4M, up 13% from Q1 2025, driven by its precision oncology portfolio. Gross profit rose to $16.6M, but higher operating expenses of $23.9M led to an operating loss of $7.3M and net loss of $8.9M, or $0.17 per share.
The company will discontinue its Resolve UTI business and close the Plano, Texas lab to refocus on prostate cancer diagnostics and the ExoDx acquisition. It issued new 2026 core cancer revenue guidance, excluding Resolve, of $110–115M, implying 20–26% year‑over‑year growth versus 2025 core cancer revenue.
Cash and cash equivalents were $43.2M as of March 31, 2026; on a pro‑forma basis after a $15.0M 2025 earnout payment to Exact Sciences, cash would have been $28.2M. MDxHealth also received a Medicare contractor recoupment decision of about $10.4M tied to historical Resolve claims, which it is contesting and has recorded as a contingent liability rather than a provision.
MDxHealth is calling ordinary and extraordinary shareholder meetings on May 28, 2026 in Ghent to approve its 2025 accounts, board mandates and auditor renewal, and to vote on several capital measures. The company proposes issuing 3,000,000 new “2026 Exact Sciences Warrants” to a subsidiary of Exact Sciences at an exercise price of USD 5.265 per share, exercisable until January 8, 2031. It also seeks approval for 3,000,000 “2026 Share Options” under a new 2026 Share Option Plan for employees, with a 10‑year term. In addition, the board asks shareholders to renew its authorized capital so it may increase share capital by up to 100% of current share capital over five years, including with the ability to restrict or cancel preferential subscription rights where allowed by law.
MDxHealth SA director Eric Bednarski filed an initial Form 3 reporting indirect holdings of 4,700,457 ordinary shares. These shares are directly owned by private investment funds managed by MVM Partners, LLC, where Bednarski is a managing member. He disclaims beneficial ownership beyond any pecuniary interest described in the footnote.
MDxHealth SA Chief Commercial Officer John Bellano filed an initial statement of beneficial ownership showing multiple share option awards over ordinary shares. The filing lists option grants from June 2019 through March 2025, with exercise prices ranging from 12.40 Euros to $1.47 per share and expirations between 2029-07-24 and 2035-04-11.
Several grants vest in three equal installments on each of the first three anniversaries of the grant date, while others vest upon the achievement of Company performance criteria evaluated by the Board of Directors at the end of specified performance periods. All positions are reported as held directly and relate to options, not current share trades.
MDxHealth SA director and Chief Executive Officer Michael McGarrity filed an initial ownership report showing his equity position in the company. The filing lists direct holdings of 95,000 Ordinary Shares and multiple share option awards over additional Ordinary Shares.
The options cover various grants that generally vest in three equal installments over three years or upon achievement of specified company performance criteria, with exercise prices ranging from €2.90–€14.90 and $1.47–$2.62, and expiration dates between 2029 and 2035. This Form 3 is a baseline disclosure and does not report new purchases or sales.
MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares. The filing lists multiple option grants with varying exercise prices in euros and U.S. dollars, different vesting schedules including performance-based vesting, and expirations extending through 2035.
MDxHealth SA Chief Financial Officer Ron Kalfus reported his existing holdings of share options over ordinary shares. The positions span multiple grants from 2019 to 2025, with strikes set in Euros and U.S. dollars and expirations running from 2029 through 2035.
They include options over 75,000 ordinary shares at an exercise price of $2.62 expiring on June 22, 2034, and 100,000 shares at $1.47 expiring on April 11, 2035. Earlier grants at prices such as 12.40, 8.00, 13.75, 6.84 and 2.90 Euros generally vest in three equal annual installments or upon achieving specified performance criteria evaluated by the Board of Directors.
MDxHealth SA director Don M. Hardison reported initial holdings of company share options. He holds options to purchase 30,000 ordinary shares at $2.62 per share, granted on June 22, 2024 and vested in full at the following annual general shareholders' meeting, and options for 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025 and vesting in full at the next annual general shareholders' meeting.
MDxHealth SA director Sanford Jay Siegel filed an initial ownership report showing compensation-related options, not a market trade. He holds options to purchase 10,000 ordinary shares at $2.18 per share, granted on June 27, 2025, vesting in full at the next-year annual general shareholders' meeting and expiring on June 27, 2035.
MDxHealth SA director Hilde Windels has filed an initial ownership report showing indirect holdings of share options in MDxHealth SA through Hilde Windels BV. The positions include options over 1,000 ordinary shares at €49.70 expiring on June 1, 2028 and 1,000 shares at €12.80 expiring on July 1, 2029. Additional grants cover 30,000 ordinary shares at $2.62 expiring on June 22, 2034 and 10,000 shares at $2.18 expiring on June 27, 2035. These options were granted in prior years and vest or vested in connection with annual general shareholders' meetings, and the reporting person disclaims beneficial ownership of securities held by Hilde Windels BV except to the extent of any pecuniary interest.